120 related articles for article (PubMed ID: 11713793)
1. Oligonucleotides--from design to the clinic.
Bennett CF
Curr Opin Mol Ther; 1999 Jun; 1(3):296. PubMed ID: 11713793
[No Abstract] [Full Text] [Related]
2. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
3. [Anti-sense in medicine and central nervous system disorders].
Cohen H; Kotler M
Harefuah; 1996 Apr; 130(7):500-2. PubMed ID: 8707227
[No Abstract] [Full Text] [Related]
4. [Antisense oligonucleotides arrest the synthesis of disease promoting proteins].
Schnädelbach S
Med Monatsschr Pharm; 1998 Dec; 21(12):394-5. PubMed ID: 9925458
[No Abstract] [Full Text] [Related]
5. Antisense oligonucleotides for haematological malignancies.
Cotter FE
Haematologica; 1999 Jun; 84 Suppl EHA-4():19-22. PubMed ID: 10907458
[No Abstract] [Full Text] [Related]
6. Preclinical and clinical pharmacology of antisense oligonucleotides.
Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM
Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide, antibody and peptide therapeutics--from design to the clinic.
Goodchild J
Curr Opin Mol Ther; 2004 Apr; 6(2):119. PubMed ID: 15195921
[No Abstract] [Full Text] [Related]
8. Antisense oligonucleotides in the design of new therapeutic strategies.
Piulats J; Tarrasón G
Methods Find Exp Clin Pharmacol; 1997; 19 Suppl A():31-2. PubMed ID: 9403853
[No Abstract] [Full Text] [Related]
9. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
10. QC in antisense oligo synthesis.
Agris PF; Smith S; Fu C; Simkins SG
Nat Biotechnol; 2002 Sep; 20(9):871-2. PubMed ID: 12205500
[No Abstract] [Full Text] [Related]
11. Antisense approaches to immune modulation for transplant and autoimmune diseases.
Mourich DV; Marshall NB
Curr Opin Pharmacol; 2005 Oct; 5(5):508-12. PubMed ID: 16087396
[TBL] [Abstract][Full Text] [Related]
12. [Prospects of a more selective chemotherapy with antisense oligonucleotides].
Le Doan T; Etoré F; David DF; Tenu JP
Ann Med Interne (Paris); 1996; 147(8):542-52. PubMed ID: 9137681
[No Abstract] [Full Text] [Related]
13. RNA-based therapeutics--from design to the clinic.
Iversen P
Curr Opin Mol Ther; 2009 Apr; 11(2):107. PubMed ID: 19330715
[No Abstract] [Full Text] [Related]
14. Antisense research.
Bennett CF
Science; 1996 Jan; 271(5248):434. PubMed ID: 8560247
[No Abstract] [Full Text] [Related]
15. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
Tolcher AW
Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
[TBL] [Abstract][Full Text] [Related]
16. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
Mahato RI; Cheng K; Guntaka RV
Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
[TBL] [Abstract][Full Text] [Related]
17. [Antisense oligonucleotides: a new class of biologically active molecules].
Uteshev DB; Korostelev SA; Sergeev AV; Uteshev BS
Eksp Klin Farmakol; 2004; 67(3):76-9. PubMed ID: 15341077
[TBL] [Abstract][Full Text] [Related]
18. In vivo studies with antisense oligonucleotides.
Akhtar S; Agrawal S
Trends Pharmacol Sci; 1997 Jan; 18(1):12-8. PubMed ID: 9114724
[No Abstract] [Full Text] [Related]
19. Overview of target validation and the impact of oligonucleotides.
Jones SW; Lindsay MA
Curr Opin Mol Ther; 2004 Oct; 6(5):546-50. PubMed ID: 15537056
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
